Eli Lilly

Lilly faces biosimilar rivals to osteoporosis drug Forsteo in Europe
Lilly faces biosimilar rivals to osteoporosis drug Forsteo in Europe
Pharmaforum
Eli Lilly
biosimilars
osteoporosis
Forsteo
Europe
Stada
Gedeon Richter
Flag link:
Lilly’s first crowdsourced digital health contest seeks solutions for IBD
Lilly’s first crowdsourced digital health contest seeks solutions for IBD
Fierce Pharma
IBD
Eli Lilly
innovation challenges
innovation
digital health
Flag link:
Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi
Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi
Reuters
Roche
Rozlytrek
Bayer
Eli Lilly
personalized medicine
Flag link:
Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt
Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt
Fierce Pharma
Eli Lilly
Taltz
JNJ
Tremfya
psoriasis
Flag link:
Most insurers don't cover Eli Lilly's half-priced insulin
Most insurers don't cover Eli Lilly's half-priced insulin
Beckers Hospital Review
insulin
diabetes
drug pricing
Eli Lilly
PBMs
insurers
Flag link:
Apple, Eli Lilly research whether devices can detect dementia signs
Apple, Eli Lilly research whether devices can detect dementia signs
Medtech Dive
Apple
Eli Lilly
dementia
wearables
devices
Evidation
Apple Watch
iPhone
Flag link:
Lilly shuffles executives overseeing oncology and M&A
Lilly shuffles executives overseeing oncology and M&A
Biopharma Dive
Eli Lilly
oncology
M&A
Flag link:
Eli Lilly confirms probe by New York’s Attorney General over insulin prices
Eli Lilly confirms probe by New York’s Attorney General over insulin prices
CNBC
Eli Lilly
drug pricing
insulin
diabetes
New York
Flag link:
Racing after the leaders, Eli Lilly's migraine drug clears another pivotal study
Racing after the leaders, Eli Lilly's migraine drug clears another pivotal study
Endpoints
Eli Lilly
Emgality
clinical trials
migraines
chronic migraine
episodic migraine
Flag link:
3 Lung Cancer Stocks That Could Soar in September
3 Lung Cancer Stocks That Could Soar in September
Motley Fool
lung cancer
Eli Lilly
Amgen
AstraZeneca
Flag link:
New York investigating 3 insulin makers' pricing strategies
New York investigating 3 insulin makers' pricing strategies
Beckers Hospital Review
New York
insulin
diabetes
Sanofi
Eli Lilly
Novo Nordisk
Flag link:
Lilly's Emgality powers ahead with 'best-in-class' CGRP access
Lilly's Emgality powers ahead with 'best-in-class' CGRP access
Fierce Pharma
Eli Lilly
Emgality
migraines
Amgen
Aimovig
Teva Pharmaceutical
Ajovy
Flag link:
Lilly cancer push boosted by survival benefit to key drug
Lilly cancer push boosted by survival benefit to key drug
Biopharma Dive
Eli Lilly
Verzenio
metastatic breast cancer
clinical trials
Flag link:
Lilly drops PD-L1/TIM-3 bispecific from clinical pipeline
Lilly drops PD-L1/TIM-3 bispecific from clinical pipeline
Fierce Biotech
Eli Lilly
bispecific antibodies
solid tumors
Flag link:
After painting a poor safety profile, Pfizer and Eli Lilly are shooting for a new pain drug OK anyway
After painting a poor safety profile, Pfizer and Eli Lilly are shooting for a new pain drug OK anyway
Endpoints
Pfizer
Eli Lilly
FDA
tanezumab
anti-TNF
Flag link:
The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate
The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate
Yahoo/Benzinga
biotech
earnings
Immunic
Alkermes
Conatus
Aevi Genomic
Tricida
Curis
Ultragenyx
Leap Therapeutics
Cidara Therapeutics
Akcea
Spark Therapeutics
Eli Lilly
AnaptysBio
clinical trials
Flag link:
In a first, Lilly's ready-to-use rescue hypoglycemia powder wins US approval
In a first, Lilly's ready-to-use rescue hypoglycemia powder wins US approval
Endpoints
Eli Lilly
FDA
hypoglycemia
Baqsimi
Flag link:
These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger
These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger
Investors Business Daily
Bristol-Myers Squibb
Celgene
M&A
Otezla
Gilead Sciences
Amgen
Regeneron
Eli Lilly
JNJ
Flag link:
Emgality-maker Lilly courts payers with new migraine ER data
Emgality-maker Lilly courts payers with new migraine ER data
Fierce Pharma
Eli Lilly
Emgality
cluster headache
migraines
Amgen
Novartis
Teva Pharmaceutical
ER
Flag link:
Amgen, Novartis BACE Inhibitor Joins List of Failed Alzheimer’s Drugs
Amgen, Novartis BACE Inhibitor Joins List of Failed Alzheimer’s Drugs
Xconomy
Alzheimer's disease
BACE inhibitors
Merck
Eli Lilly
AstraZeneca
Amgen
Novartis
Biogen Eisai
Flag link:

Pages